ATE499102T1 - Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen - Google Patents

Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen

Info

Publication number
ATE499102T1
ATE499102T1 AT07759007T AT07759007T ATE499102T1 AT E499102 T1 ATE499102 T1 AT E499102T1 AT 07759007 T AT07759007 T AT 07759007T AT 07759007 T AT07759007 T AT 07759007T AT E499102 T1 ATE499102 T1 AT E499102T1
Authority
AT
Austria
Prior art keywords
cell proliferation
proliferation disorders
pyrimidinediamine compounds
treating cell
cell proliferative
Prior art date
Application number
AT07759007T
Other languages
German (de)
English (en)
Inventor
Esteban Masuda
Donald Payan
Elliott Grossbard
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE499102T1 publication Critical patent/ATE499102T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07759007T 2006-04-18 2007-03-21 Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen ATE499102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/407,233 US8227455B2 (en) 2005-04-18 2006-04-18 Methods of treating cell proliferative disorders
PCT/US2007/064511 WO2007124221A1 (en) 2006-04-18 2007-03-21 Methods of treating cell proliferative disorders by using pyrimidinediamine compounds

Publications (1)

Publication Number Publication Date
ATE499102T1 true ATE499102T1 (de) 2011-03-15

Family

ID=38477280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07759007T ATE499102T1 (de) 2006-04-18 2007-03-21 Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen

Country Status (10)

Country Link
US (2) US8227455B2 (enExample)
EP (1) EP2010181B1 (enExample)
JP (1) JP5204761B2 (enExample)
AT (1) ATE499102T1 (enExample)
CA (1) CA2649549C (enExample)
DE (1) DE602007012677D1 (enExample)
DK (1) DK2010181T3 (enExample)
ES (1) ES2364657T3 (enExample)
SI (1) SI2010181T1 (enExample)
WO (1) WO2007124221A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365223T3 (es) * 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
US8227455B2 (en) * 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090048214A1 (en) * 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
UA102825C2 (ru) * 2007-11-07 2013-08-27 Райджел Фармасьютикалз, Инк. Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
HUE028589T2 (en) 2008-07-10 2016-12-28 Toray Industries Pharmaceutical preparation for the treatment and prevention of cancer
EP2387572B1 (en) * 2009-01-15 2015-09-16 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8389515B2 (en) * 2009-11-20 2013-03-05 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs and their uses
JP6067550B2 (ja) 2010-04-13 2017-01-25 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
PL2589592T3 (pl) 2010-06-30 2019-03-29 Fujifilm Corporation Nowe pochodne nikotynamidu lub ich sole
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
AU2012288632B2 (en) 2011-07-28 2017-08-17 Rigel Pharmaceuticals, Inc. New (trimethoxyphenylamino)pyrimidinyl formulations
ES2661444T3 (es) 2011-12-28 2018-04-02 Fujifilm Corporation Nuevo derivado de nicotinamida o sal del mismo
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
CN103958526B (zh) * 2012-06-20 2015-09-09 上海恒瑞医药有限公司 嘧啶二胺类衍生物、其制备方法及其在医药上的应用
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103102412B (zh) * 2013-01-29 2014-03-26 陈仁杰 人源抗鼻咽癌LMP2A胞外区抗体Fab及其应用
JP6707549B2 (ja) * 2015-01-23 2020-06-10 エラスムス ユニバーシティ メディカルセンター ロッテルダムＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｒｏｔｔｅｒｄａｍ 抗老化化合物及びその使用
ES2913119T3 (es) * 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
RU2621187C1 (ru) * 2016-05-13 2017-06-01 Общество с ограниченной ответственностью "Молекулярные Технологии" Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
PT3773589T (pt) 2018-04-03 2024-02-06 Blueprint Medicines Corp Inibidor de ret para utilização no tratamento de cancro com alteração de ret
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
JPWO2023182460A1 (enExample) * 2022-03-24 2023-09-28
WO2024037910A1 (en) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE69822514T2 (de) * 1997-12-31 2005-03-24 The University Of Kansas, Lawrence Wasserlösliche pro-pharmaka von arzneistoffen, die ein tertiäres amin enthalten, und verfahren zu ihrer herstellung
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DK1343782T3 (da) 2000-12-21 2009-08-24 Smithkline Beecham Corp Pyrimidinaminer som angiogenesemodulatorer
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
NZ535365A (en) * 2002-03-20 2006-07-28 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
IL166241A0 (en) * 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
AU2003260344A1 (en) 2002-08-02 2004-02-25 Vanetta S.P.A. Redox process particularly for the production of menadione and use of polyoxometalates
JP2006524688A (ja) 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
RS53109B (sr) * 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
WO2005027848A2 (en) 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
US7750160B2 (en) * 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
ES2380550T3 (es) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
NZ555947A (en) * 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds

Also Published As

Publication number Publication date
CA2649549A1 (en) 2007-11-01
WO2007124221A1 (en) 2007-11-01
US8481521B2 (en) 2013-07-09
ES2364657T3 (es) 2011-09-08
US20060276459A1 (en) 2006-12-07
JP5204761B2 (ja) 2013-06-05
EP2010181A1 (en) 2009-01-07
DE602007012677D1 (de) 2011-04-07
US8227455B2 (en) 2012-07-24
SI2010181T1 (sl) 2011-06-30
CA2649549C (en) 2011-10-18
DK2010181T3 (da) 2011-06-14
JP2009534397A (ja) 2009-09-24
US20120245127A1 (en) 2012-09-27
EP2010181B1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
ATE499102T1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
EA201590230A1 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
ATE438650T2 (de) Proteasominhibitoren und verfahren zu deren anwendung
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
PH12014501355B1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
PH12015500181A1 (en) Atx modulating agents
IL184678A0 (en) Proteasome inhibitors and methods of using the same
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
EA201401062A1 (ru) Бициклические пиразиноновые производные
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
MY162518A (en) Proteasome inhibitors and methods of using the same
EA201791179A1 (ru) Дейтерированный триазолопиридазин в качестве модулятора киназы
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties